Continuing Education Activity

Melasma is a common acquired disorder of hyperpigmentation that presents persistent diagnostic and therapeutic challenges in dermatologic practice. The condition predominantly affects sun-exposed facial areas and appears as symmetric brown-to-gray macules and patches. Pathogenesis is multifactorial, involving ultraviolet and visible light exposure, hormonal influences, genetic susceptibility, and contributions from the vasculature and dermis. Risk factors include female sex, pregnancy, oral contraceptive use, and positive family history. Melasma typically follows a chronic, relapsing course and may be associated with significant psychosocial distress. Diagnosis relies on clinical distribution, Wood lamp examination, and selective histopathologic evaluation to support classification and prognosis. Management emphasizes long-term control through photoprotection, patient education, and individualized treatment strategies rather than relying solely on short-term pigment clearance. Recurrence and treatment-related adverse effects remain common challenges.

This educational activity enhances clinician competence in the comprehensive evaluation and management of melasma. Participants deepen their understanding of etiology, risk factors, pathogenesis, and clinical presentation while strengthening their skills in diagnostic assessment and in selecting evidence-based topical, oral, and procedural therapies. Instruction highlights individualized treatment planning, prevention of recurrence, and mitigation of adverse effects through sustained photoprotection and patient counseling. Collaboration with an interprofessional healthcare team, including dermatology nurses, pharmacists, and aesthetic specialists, supports coordinated care, improves therapy adherence, and promotes durable clinical outcomes for individuals with melasma.

Objectives:

• Differentiate melasma from other facial hyperpigmentation disorders, including postinflammatory hyperpigmentation, lentigines, and drug-induced pigmentation, using clinical and diagnostic features.
• Implement evidence-based, personalized strategies for managing melasma and mitigating any possible complications.
• Improve patient awareness of melasma treatment limitations, recurrence risk, and the necessity of ongoing preventive strategies.
• Collaborate with the interprofessional team to educate, treat, and monitor patients with melasma to improve overall health outcomes.

Access free multiple choice questions on this topic.

Introduction

Melasma is a common acquired hyperpigmentation disorder characterized by symmetric, irregularly bordered brown-to-gray macules and patches that predominantly involve sun-exposed facial skin (see Image. Melasma of the Midface and Lower Face). Commonly affected regions include the centrofacial, malar, and mandibular areas. Extrafacial involvement has also been described, particularly in individuals with chronic sun exposure.[1]

Melasma is widely regarded as a chronic, relapsing pigmentary disorder in which long-term disease control and prevention of recurrence are as important as initial pigment clearance.[2] Clinical improvement is frequently transient in the absence of sustained photoprotection and maintenance therapy, a characteristic that distinguishes melasma from other acquired hyperpigmentation disorders.[3] Contemporary pathogenic models emphasize that melasma extends beyond isolated melanocyte hyperactivity and involves complex interactions among keratinocytes, fibroblasts, endothelial cells, inflammatory mediators, and the dermal extracellular matrix.[4]

These insights have reframed melasma as a disorder characterized by overlapping features of photoaging, vascular dysregulation, and altered dermal signaling, rather than as a purely epidermal pigmentary condition.[5] Given its facial predilection and chronic course, melasma is associated with substantial quality-of-life impairment, including emotional distress, social embarrassment, and reduced self-esteem.[6][7] Results from recent studies using validated instruments demonstrate that disease severity does not consistently correlate with patient-perceived burden, reinforcing the importance of individualized counseling and expectation management.[8]

Etiology

Melasma is multifactorial and involves interactions among ultraviolet (UV) radiation, visible light exposure, hormonal influences, genetic susceptibility, and alterations in the cutaneous microenvironment. Among these factors, chronic light exposure represents the most consistent and modifiable trigger, contributing to both disease onset and relapse. UV radiation stimulates melanogenesis through activation of melanocyte-stimulating hormone pathways, inflammatory mediators, and oxidative stress, whereas visible light—particularly short-wavelength blue light—has emerged as a clinically significant contributor, especially in individuals with darker skin phototypes.[9] Results from clinical and histologic studies indicate that visible-light–induced pigmentation may be more intense and longer-lasting than UV-induced pigmentation, supporting the use of expanded photoprotection strategies in the management of melasma.[10]

Hormonal influences are strongly implicated, as evidenced by the frequent onset or exacerbation of melasma during pregnancy or exogenous estrogen or progesterone exposure. Estrogen receptor expression in melanocytes and adjacent keratinocytes may enhance melanogenic responsiveness to UV radiation and inflammatory stimuli. Genetic susceptibility is supported by familial clustering and increased prevalence in certain ethnic populations, suggesting inherited differences in melanocyte activity, vascular responsiveness, and inflammatory signaling. These genetic influences appear to modulate individual sensitivity to environmental and hormonal triggers rather than function as isolated causative determinants.

Emerging evidence highlights dermal and vascular alterations, including basement membrane disruption and solar elastosis, which may sustain melanocyte stimulation and promote pigment retention.[11] Increased vascularity and angiogenic signaling associated with vascular endothelial growth factor have also been demonstrated in melasma lesions, supporting a vascular contribution to disease persistence.[12] This expanded etiologic framework has fueled ongoing debate over whether melasma should be classified as a primary pigmentary disorder or as a manifestation of photoaging with secondary hyperpigmentation.

Epidemiology

Melasma occurs worldwide; however, reported prevalence varies substantially by geography, ancestry, and sampling setting (community-based versus clinic-based cohorts), limiting the precision of single global prevalence estimates. Across published studies, melasma disproportionately affects individuals with Fitzpatrick skin types III to V and is most frequently observed in populations with higher baseline facultative pigmentation and greater cumulative photic exposure. Melasma predominantly affects women, with most series demonstrating a marked predominance in women, although men are also affected and may constitute a clinically meaningful minority in certain regions and clinic populations.[13] Age of onset most commonly occurs during reproductive years, and disease is uncommon before puberty, supporting an interaction between hormonal milieu and light exposure. Pregnancy-associated melasma is well described, with pregnancy-related prevalence estimates varying widely across populations and study designs.

In the United States (US), large modern database analyses demonstrate that melasma is diagnosed across diverse racial and ethnic groups, with disproportionate burden reported among Hispanic-Latino and Asian individuals in national cohorts.[14] US cohort data also reveal associations between melasma and comorbid inflammatory and vascular conditions (eg, rosacea) as well as exposure to hormonal contraception, although causality cannot be inferred from cross-sectional analyses.[15] Community-based prevalence estimates in specific US populations, such as Latino women in the Southwestern US, indicate that prevalence can be substantial in selected at-risk groups and support the clinical impression that melasma is undercaptured when relying solely on clinic-based data.

Extrafacial melasma is relatively uncommon and may exhibit distinct demographic patterns, often observed among postmenopausal patients. However, the evidence base is limited and subject to selection bias.[16] Overall, epidemiologic data support 2 clinically practical points: melasma is frequently encountered in dermatologic practice, and the risk is highest when light exposure and hormonal influences coexist in genetically predisposed individuals.

Pathophysiology

Melasma is a multifactorial dyschromia arising from external triggers (particularly solar radiation), hormonal influences, and inflammatory or irritant factors in genetically predisposed individuals. Modern mechanistic models emphasize that melasma does not reflect a purely epidermal melanocyte disorder, but instead involves dysregulated epidermal–dermal crosstalk among keratinocytes, fibroblasts, endothelial cells, and immune mediators, collectively sustaining melanogenesis and contributing to relapse.[17] Visible light, including short-wavelength “blue” light, can induce persistent pigmentation and may be particularly relevant in individuals with darker phototypes, supporting the concept that melasma is maintained by broader photic inputs than UV alone. Dermal changes that overlap with photoaging, such as basement membrane disruption, solar elastosis, neovascularization, mast cell enrichment, and subclinical inflammation, are increasingly recognized as integral to the persistence of melasma and to treatment resistance.[18] Increased vascularity and proangiogenic signaling, including vascular endothelial growth factor expression, have been repeatedly demonstrated in melasma lesions. These findings provide a biologic rationale for therapies that indirectly target vascular and inflammatory drivers in selected patients.

Histopathology

Histopathology in melasma is heterogeneous and often reflects both pigmentary and photoaging-associated dermal alterations, with features that vary by disease duration, skin phototype, and cumulative sun exposure. Epidermal findings frequently include increased melanin within basal and suprabasal keratinocytes and variable prominence of melanocyte dendricity, whereas melanocyte numbers are often not markedly elevated, supporting hyperfunctional melanogenesis as a core feature. Dermal involvement is a consistent theme in contemporary analyses. Many patients exhibit solar elastosis, basement membrane disruption, and melanin incontinence with dermal melanophages, which contribute to the clinical impression of “dermal” or “mixed” melasma, as well as slower or incomplete pigment clearance. Basement membrane disruption and “pendulous” melanocytes have been reported, supporting a mechanism by which chronic photodamage facilitates pigment transfer or “dropout” into the dermis, where pigment demonstrates greater resistance to clearance.

Dermal inflammatory and stromal changes are reported in melasma, including increased mast cells, neovascularization, and subclinical inflammation, which may amplify melanogenesis through cytokine signaling and vasculature–melanocyte interactions. Increased vascularity is a reproducible histologic and immunohistochemical finding, with evidence implicating vascular endothelial growth factor in the modulation of dermal vessels. The classical clinical shorthand of “epidermal versus dermal versus mixed” should be considered a pragmatic therapeutic framework rather than a strict histopathologic classification, particularly given sampling variability and the limitations of noninvasive depth estimation.[19]

History and Physical

The diagnosis of melasma is primarily clinical and begins with a detailed history focused on onset, chronicity, and known triggers, including cumulative sun exposure, pregnancy, and exogenous hormonal use. Gradual onset with episodic worsening during periods of increased UV or visible-light exposure is frequently reported, underscoring the condition's chronic, relapsing nature. Hormonal history is critical, as melasma commonly develops or worsens during pregnancy or use of oral contraceptives or hormone replacement therapy. A family history of melasma or other pigmentary disorders may support a genetic predisposition that modulates susceptibility to environmental triggers.

On physical examination, melasma presents as symmetrical, hyperpigmented macules and patches with irregular borders and uniform coloration, predominantly affecting the face. Classic facial distribution patterns include centrofacial, malar, and mandibular involvement, with centrofacial distribution being most common (see Image. Midface Melasma with Supraorbital Involvement). Lesions are nonscaly, nonindurated, and asymptomatic, distinguishing the condition from inflammatory dermatoses that may also cause facial hyperpigmentation.

Extrafacial melasma is less common and typically occurs in chronically sun-exposed areas, such as the forearms and neck. Extrafacial involvement is observed more frequently in postmenopausal individuals. Disease severity on examination does not reliably correlate with patient-reported distress, emphasizing the importance of evaluating psychosocial impact and patient goals during clinical encounters.

Evaluation

Melasma is primarily a clinical diagnosis, and routine laboratory testing is not indicated in typical cases. Diagnostic evaluation focuses on confirming the diagnosis, assessing disease extent, and identifying exacerbating factors that may influence management. Historically, Wood lamp examination was used to classify melasma as epidermal, dermal, or mixed. Contemporary literature demonstrates that Wood lamp findings are inconsistent, particularly in individuals with darker skin phototypes, and should not guide prognosis or treatment decisions. Consequently, routine use of this diagnostic method has declined in favor of comprehensive clinical evaluation.

Dermoscopy has emerged as a valuable adjunctive assessment modality in melasma, enabling visualization of pigment distribution patterns and vascular structures, including background erythema and telangiectasias, which may indicate dermal involvement and photoaging-related changes.[20] Dermoscopic features such as a brown reticular or pseudoreticular pigment network, diffuse light-to-dark brown background pigmentation, perifollicular or periappendageal sparing, and telangiectatic vessels can support the clinical diagnosis and facilitate lesion characterization (see Image. Treatment-Refractory Melasma in a 35-Year-Old Woman with Mild Photosensitivity).[21] Advanced imaging tools, such as reflectance confocal microscopy, show increased epidermal melanin, dermal melanophages with pigment incontinence, and alterations in dermal structure and vasculature. 

However, the use of these modalities remains largely confined to research laboratories and specialized clinical centers equipped with the necessary technology and expertise.[22] These techniques are not required for routine diagnosis but have contributed substantially to the current understanding of melasma pathophysiology.[23] Laboratory evaluation for endocrine disorders is not routinely indicated unless the clinical context suggests atypical presentation or signs of hormonal dysregulation. International consensus statements and expert reviews emphasize that overinvestigation should be avoided, with management directed toward modifiable triggers, photoprotection, and patient-centered treatment planning.

Treatment / Management

Melasma management is best conceptualized as chronic disease control rather than cure, with emphasis on 3 strategies: trigger reduction, particularly photoprotection; induction therapy to achieve pigment lightening; and long-term maintenance to reduce relapse.[24] Recent expert consensus recommendations further emphasize a multimodal approach that integrates photoprotection, supervised use of hydroquinone-based regimens when indicated, and individualized maintenance strategies.[25]

Photoprotection

Rigorous daily photoprotection is essential for all patients and should be maintained indefinitely, as melasma recurrence is strongly driven by ongoing exposure to UV and visible light. Because visible light can contribute to pigmentation in susceptible individuals, recent reviews and photoprotection literature support the preferential use of tinted formulations containing pigmentary filters (eg, iron oxides) to reduce visible-light–induced pigmentation relevant to melasma.[26] Clinical studies in 2025 substantiate the value of iron oxide–containing formulations for patients with melasma, providing additional real-world evidence for visible-light–aware sunscreen regimens.[27]

Topical Therapies

Topical therapy remains the cornerstone of melasma management and is typically applied in induction (clearance-focused) and maintenance phases. Hydroquinone is widely regarded as a highly effective depigmenting agent when used in supervised courses, and expert recommendations commonly position hydroquinone-based regimens, often in combination, as first-line induction therapy for many patients. Triple-combination creams, such as fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%, are frequently employed for this purpose. Consensus-based best-practice approaches emphasize careful patient selection, limited-duration hydroquinone courses, and transition to non-hydroquinone maintenance to minimize adverse effects that can exacerbate pigmentation, such as irritant dermatitis.

Nonhydroquinone topical agents are important both as alternatives for intolerance and as maintenance strategies. Contemporary reviews summarize supportive evidence for agents including azelaic acid, cysteamine, kojic acid, topical retinoids, and newer combination regimens.[28] Avoidance of irritation remains a key principle, as irritant contact dermatitis and subclinical inflammation can perpetuate hyperpigmentation and contribute to treatment failure.

Oral Tranexamic Acid

Oral tranexamic acid (TXA) has accumulated a substantial evidence base as an adjunctive therapy for melasma, with meta-analyses and network meta-analyses demonstrating clinically meaningful improvement across multiple delivery routes and regimens.[29] Contemporary reviews emphasize that dosing, duration, and patient selection vary across studies and that safety screening is essential, as TXA is an antifibrinolytic, and thromboembolic risk must be considered in susceptible individuals.[30] TXA has been evaluated via oral, topical, and intralesional routes, with oral therapy frequently demonstrating the most consistent efficacy in refractory disease, although each route entails distinct considerations regarding adverse effects.[31]

A practical, evidence-aligned approach considers oral TXA for patients with moderate-to-severe or refractory melasma as an adjunct to topical therapy and photoprotection. Careful screening for contraindications, particularly prothrombotic factors such as a history of thrombosis, thrombophilia, current or planned pregnancy, and estrogen-containing contraception, is essential, and treatment decisions should involve shared decision-making. Recent 2025 randomized trial data expand the evidence base for oral TXA, including direct comparisons of oral versus topical TXA for melasma.[32] Among appropriately selected patients, a multicenter propensity score–matched electronic health record cohort found no association between oral TXA use for melasma and thromboembolism, supporting cautious, screened application.[33]

Topical and procedural use of TXA is increasingly investigated, including microneedling-assisted and intradermal administration, providing adjunctive options for patients unsuitable for systemic therapy.[34] Results from recent studies from 2025 further support the exploration of intradermal and topical TXA formulations as adjunctive options, although variability in technique and limited follow-up limit generalizability.[35] A 2025 randomized trial comparing niosomal TXA-niacinamide formulations with hydroquinone highlights the rapid evolution of topical and vehicle science in melasma and emphasizes the need for replication and assessment of long-term relapse outcomes.[36]

Chemical Peels and Other Procedures

Superficial chemical peels, such as glycolic acid–based regimens, serve as useful adjuncts when combined with topical therapy and strict photoprotection, particularly for epidermal-predominant disease in carefully selected patients. Consensus recommendations emphasize cautious selection of techniques and diligent postprocedural photoprotection, especially in skin of color, because postinflammatory hyperpigmentation (PIH) can exacerbate melasma. Energy-based procedures are among the most debated areas in melasma management. Outcomes vary, as some patients experience improvement while others develop relapse or PIH, particularly with aggressive settings or inadequate photoprotection.

A conservative perspective reserves lasers for selected refractory cases, applies them only after optimization of photoprotection and topical regimens, and delivers them with rigorous periprocedural relapse-prevention measures to minimize PIH and rebound hyperpigmentation. Modern protocols, including low-fluence approaches, careful patient selection, and combination regimens, may benefit selected patients, but transparent counseling regarding relapse and PIH risk remains essential. Collaboration with procedural dermatologists and trained staff ensures appropriate patient selection, conservative parameter choices, and robust postprocedure photoprotection to reduce PIH and rebound hyperpigmentation.[37]

Differential Diagnosis

The differential diagnosis of facial hyperpigmentation is broad, and clinical evaluation must exclude conditions that mimic melasma in distribution or color. Common mimickers include PIH, often following an inflammatory dermatosis; lichen planus pigmentosus, including facial variants; erythema dyschromicum perstans; drug-induced hyperpigmentation; and pigmented contact dermatitis. Exogenous ochronosis should be considered in patients with long-term hydroquinone exposure who develop paradoxical blue-black pigmentation and treatment resistance, particularly in darker phototypes. Dermoscopy can assist in differentiating melasma from other causes of facial pigmentation by revealing pigment patterning and vascular alterations, although findings require interpretation within the broader clinical context.

Prognosis

Melasma typically follows a chronic, relapsing course. Significant improvement is often achieved with consistent therapy, but complete and durable clearance is less predictable without long-term maintenance. Relapse risk is influenced by ongoing light exposure, hormonal drivers, skin phototype, degree of dermal involvement and photoaging changes, and adherence to photoprotection and maintenance therapy. Therapeutic durability improves when treatment plans explicitly incorporate a maintenance phase, combined with ongoing visible-light–aware photoprotection.

Complications

The most clinically relevant complications of melasma relate to treatment-associated adverse effects and disease burden, as the condition itself is benign and nonpremalignant. Irritant dermatitis from topical regimens can exacerbate pigmentation through inflammation, highlighting the importance of barrier-supportive skincare and careful regimen selection. Procedure-associated postinflammatory dyspigmentation represents a major risk when chemical peels or lasers are applied without proper technique or adequate photoprotection, particularly in patients with darker skin phototypes.

Psychosocial morbidity constitutes another significant consequence, with reduced quality of life often occurring independently of clinician-rated disease severity. These findings support routine patient counseling and alignment of treatment goals with patient expectations.[38] For oral TXA, the primary potential complication is thrombotic risk in susceptible individuals, underscoring the need for careful screening and risk stratification as recommended in evidence syntheses and expert consensus statements.

Deterrence and Patient Education

Patient education should emphasize that melasma is chronic and relapse-prone, with long-term outcomes dependent on consistent photoprotection and maintenance therapy rather than short-term treatment bursts. Counseling should specifically address visible-light exposure and practical strategies for daily adherence, including the use of tinted photoprotection containing iron oxides and appropriate reapplication behaviors compatible with work and cosmetic routines.[39] Emerging 2025 data supporting iron oxide–containing regimens provide rationale to motivate adherence and explain the value of tinted products in melasma. Patients should be advised to avoid irritant skincare practices, aggressive exfoliation, and unmonitored combination bleaching agents, as these interventions can exacerbate hyperpigmentation. When oral TXA is considered, education must include its off-label status in many settings, the expected time course of response, the risk of relapse after discontinuation, and a clear discussion of thrombotic contraindications and warning signs.

Enhancing Healthcare Team Outcomes

Optimizing outcomes in melasma requires coordinated, patient-centered care that integrates medical management, behavioral adherence, and psychosocial support. Dermatologists play a central role in diagnosis, trigger identification, selection of induction and maintenance regimens, and counseling regarding realistic expectations and relapse prevention. Advanced practitioners and nurses enhance outcomes through structured education on photoprotection techniques, including tinted lenses and visible-light–aware strategies, troubleshooting adherence, and early identification of irritant dermatitis or PIH that may necessitate regimen modification.

Pharmacists contribute by counseling on correct topical application, mitigating irritation, identifying interacting medications or contraindications—particularly when oral TXA is prescribed—and supporting adherence to time-limited hydroquinone courses with appropriate transition to maintenance therapy. For patients undergoing procedures, collaboration with procedural dermatologists and trained staff ensures appropriate patient selection, conservative parameter choices, and robust postprocedure photoprotection to minimize PIH and rebound hyperpigmentation. The healthcare team should also recognize the substantial psychosocial burden associated with melasma, assess the impact on quality of life, and incorporate shared decision-making to align treatment intensity with patient preferences and safety considerations.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017 Sep;7(3):305-318. [PMC free article: PMC5574745] [PubMed: 28726212]

2.

Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011 Oct;65(4):689-697. [PubMed: 21920241]

3.

Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014 Sep-Oct;89(5):771-82. [PMC free article: PMC4155956] [PubMed: 25184917]

4.

Espósito ACC, Cassiano DP, da Silva CN, Lima PB, Dias JAF, Hassun K, Bagatin E, Miot LDB, Miot HA. Update on Melasma-Part I: Pathogenesis. Dermatol Ther (Heidelb). 2022 Sep;12(9):1967-1988. [PMC free article: PMC9464278] [PubMed: 35904706]

5.

Passeron T. Melasma pathogenesis and influencing factors - an overview of the latest research. J Eur Acad Dermatol Venereol. 2013 Jan;27 Suppl 1:5-6. [PubMed: 23205539]

6.

Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003 Sep;149(3):572-7. [PubMed: 14510991]

7.

Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat. 2007;18(1):5-9. [PubMed: 17365259]

8.

Zhu Y, Zeng X, Ying J, Cai Y, Qiu Y, Xiang W. Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis. PLoS One. 2022;17(1):e0262833. [PMC free article: PMC8794204] [PubMed: 35085327]

9.

Duteil L, Cardot-Leccia N, Queille-Roussel C, Maubert Y, Harmelin Y, Boukari F, Ambrosetti D, Lacour JP, Passeron T. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res. 2014 Sep;27(5):822-6. [PubMed: 24888214]

10.

Lim HW, Kohli I, Granger C, Trullàs C, Piquero-Casals J, Narda M, Masson P, Krutmann J, Passeron T. Photoprotection of the Skin from Visible Light‒Induced Pigmentation: Current Testing Methods and Proposed Harmonization. J Invest Dermatol. 2021 Nov;141(11):2569-2576. [PubMed: 34112516]

11.

Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, Sohn S, Im S. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002 Feb;146(2):228-37. [PubMed: 11903232]

12.

Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007 May;46(2):111-6. [PubMed: 17363223]

13.

Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011 Jul;56(4):380-2. [PMC free article: PMC3178998] [PubMed: 21965843]

14.

Hill RC, Stubblefield O, Lipner SR. Asian and Hispanic/Latino Patients Are High Risk for Melasma Development in a Cross-Sectional Cohort Study Using the All of Us Database. J Cutan Med Surg. 2024 Jul-Aug;28(4):399-400. [PubMed: 38591407]

15.

Sharma AN, Kincaid CM, Mesinkovska NA. The Burden of Melasma: Race, Ethnicity, and Comorbidities. J Drugs Dermatol. 2024 Aug 01;23(8):691-693. [PubMed: 39093647]

16.

Daroach M, Vinay K, Bishnoi A, Parsad D, Kumaran MS. Extrafacial Melasma: A Scenario Less Explored. Indian Dermatol Online J. 2022 Jul-Aug;13(4):484-486. [PMC free article: PMC9574139] [PubMed: 36262579]

17.

Liu W, Chen Q, Xia Y. New Mechanistic Insights of Melasma. Clin Cosmet Investig Dermatol. 2023;16:429-442. [PMC free article: PMC9936885] [PubMed: 36817641]

18.

Phansuk K, Vachiramon V, Jurairattanaporn N, Chanprapaph K, Rattananukrom T. Dermal Pathology in Melasma: An Update Review. Clin Cosmet Investig Dermatol. 2022;15:11-19. [PMC free article: PMC8747646] [PubMed: 35023942]

19.

Kwon SH, Na JI, Choi JY, Park KC. Melasma: Updates and perspectives. Exp Dermatol. 2019 Jun;28(6):704-708. [PubMed: 30422338]

20.

Sonthalia S, Jha AK, Langar S. Dermoscopy of Melasma. Indian Dermatol Online J. 2017 Nov-Dec;8(6):525-526. [PMC free article: PMC5707865] [PubMed: 29204416]

21.

Rattananukrom T, Suchonwanit P, Thadanipon K, Vachiramon V. A Comparative Study of Dermatoscopic Features of Melasma and Hori's Nevus in Asian Patients. J Clin Aesthet Dermatol. 2022 Mar;15(3):16-20. [PMC free article: PMC8944292] [PubMed: 35342501]

22.

Kang HY, Bahadoran P, Suzuki I, Zugaj D, Khemis A, Passeron T, Andres P, Ortonne JP. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol. 2010 Aug;19(8):e228-33. [PubMed: 20497220]

23.

Guida S, Longo C, Ronga R, Stabile G, Podo Brunetti A, Bigotto GD, Conforti C, Ciardo S, Cantisani C, Paolino G, Mercuri SR, Nisticò SP, Zerbinati N, Rongioletti F, Pellacani G. Melasma and reflectance confocal microscopy: from baseline to treatment monitoring. Int J Dermatol. 2024 Aug;63(8):1007-1012. [PubMed: 38448367]

24.

Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Best practices in the treatment of melasma with a focus on patients with skin of color. J Am Acad Dermatol. 2024 Feb;90(2):269-279. [PubMed: 37748556]

25.

Sarkar R, Desai SR, Sinha S, Dogra S, Arellano-Mendoza MI, Ailawadi P, Aurangabadkar S, Bagatin E, Barua S, Bhalla M, Cassiano D, Cestari T, Das A, Dayrit J, Dlova N, Lan CE, Elbuluk N, Espósito AC, Handog E, Jagadeesan S, Katoch S, Sendhil Kumaran M, Kumarasinghe P, Macarayo MJ, Miot HA, Mysore V, Narayan R V, Oh SH, Passeron T, Picardo M, Podder I, Sachdeva S, Sharma A, Sharma R, Somani V, Swarnkar B, Taylor S, Thappa DM, Vinay K, Lim HW. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2026 Apr;40(4):680-692. [PubMed: 40996222]

26.

Lyons AB, Trullas C, Kohli I, Hamzavi IH, Lim HW. Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens. J Am Acad Dermatol. 2021 May;84(5):1393-1397. [PubMed: 32335182]

27.

Grimes PE, Paturi J, Chen Y, Wangari-Olivero J, Dumbuya H, Yan X, Lynch S, Zheng Q. Photoprotection Efficacy of Sun Protection Factor and Iron Oxide Formulations in Diverse Skin With Melasma and Photodamage. J Drugs Dermatol. 2025 Jul 01;24(7):662-667. [PubMed: 40627587]

28.

Jo JY, Chae SJ, Ryu HJ. Update on Melasma Treatments. Ann Dermatol. 2024 Jun;36(3):125-134. [PMC free article: PMC11148313] [PubMed: 38816973]

29.

Liang R, Luo H, Pan W, Yang S, Peng X, Kuang B, Huang H, Liu C. Comparative efficacy and safety of tranexamic acid for melasma by different administration methods: A systematic review and network meta-analysis. J Cosmet Dermatol. 2024 Apr;23(4):1150-1164. [PubMed: 38059683]

30.

Gan C, Rodrigues M. An Update on New and Existing Treatments for the Management of Melasma. Am J Clin Dermatol. 2024 Sep;25(5):717-733. [PMC free article: PMC11358250] [PubMed: 38896402]

31.

Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023 Apr;22(4):1197-1206. [PubMed: 36606378]

32.

Heidary B, Meibodi GAH, Ardakani ME, Ramezani V, Heidari F. Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma. J Cosmet Dermatol. 2025 Sep;24(9):e70428. [PMC free article: PMC12418907] [PubMed: 40923777]

33.

Hernandez T, Penny K, Culotta N. Oral tranexamic acid use for melasma is not associated with thromboembolism: Findings from a multicenter propensity score-matched electronic health record cohort. JAAD Int. 2026 Feb;24:64-66. [PMC free article: PMC12621489] [PubMed: 41256337]

34.

Feng X, Su H, Xie J. The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: A systematic review and meta-analysis. J Cosmet Dermatol. 2024 Jan;23(1):33-43. [PubMed: 37584240]

35.

Hosfiar VA, Sitohang IBS, Rahmayunita G. Effectiveness and Safety of Intradermal Tranexamic Acid Injection as an Adjunctive Treatment for Melasma in Skin Type IV-V: A Double-blind Randomized Controlled Trial. J Clin Aesthet Dermatol. 2025 Jul 01;18(7):30-34. [PMC free article: PMC12327562] [PubMed: 40778014]

36.

Ghasemiyeh P, Haghighi NF, Dastgheib L, Ranjbar S, Mohammadi-Samani S. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial. Sci Rep. 2025 Nov 28;15(1):42739. [PMC free article: PMC12663283] [PubMed: 41315336]

37.

Jiryis B, Toledano O, Avitan-Hersh E, Khamaysi Z. Management of Melasma: Laser and Other Therapies-Review Study. J Clin Med. 2024 Mar 03;13(5) [PMC free article: PMC10932414] [PubMed: 38592701]

38.

Feldman SR, Liguori A, Kucenic M, Rapp SR, Fleischer AB, Lang W, Kaur M. Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. J Am Acad Dermatol. 2004 Jul;51(1):45-51. [PubMed: 15243523]

39.

Morgado-Carrasco D, Delgado J, Prudkin-Silva L, Santamaria J, Piquero-Casals J. Sunscreens prescribed to patients with skin of color and/or with melasma: A survey of 221 dermatologists and dermatology residents in Spain. Photodermatol Photoimmunol Photomed. 2024 Sep;40(5):e12996. [PubMed: 39149878]

Disclosure: Nishad Sathe declares no relevant financial relationships with ineligible companies.

Disclosure: Marjorie Launico declares no relevant financial relationships with ineligible companies.